Etanercept reduces inflammation in patients with the metabolic syndrome

  • Published 2006 in
    Nature Clinical Practice Endocrinology…

Abstract

Etanercept is currently approved by the FDA to treat patients with inflammatory arthritis. Here, Bernstein et al. assessed the effects of etanercept on markers of inflammation associated with tumor necrosis factor (TNF) production, in patients with the metabolic syndrome. In these patients, adipocytes secrete cytokines such as TNF that trigger an… (More)
DOI: 10.1038/ncpendmet0214

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics